L. Benajiba

发表

TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration

B. Dubois, V. Meininger, F. Salachas, 2009, Annals of neurology.

Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease

E. Clappier, C. Preudhomme, P. Fenaux, 2021, Leukemia.

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

X. Paoletti, J. Soria, V. Ribrag, 2018, Investigational New Drugs.

Rare melanocortin-3 receptor mutations with in vitro functional consequences are associated with human obesity.

K. Clément, P. Galan, S. Hercberg, 2011, Human molecular genetics.

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

T. Barbui, A. Patriarca, P. Guglielmelli, 2021, Blood Cancer Journal.

The Folate Cycle Enzyme MTHFR is a Critical Regulator of Cell Response to MYC-Targeting Therapies.

K. Stegmaier, J. Qi, H. Dombret, 2019, Cancer discovery.

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

K. Stegmaier, M. Hemann, G. Alexe, 2016 .

Long-term follow-up of recovered MPN patients with COVID-19

T. Barbui, A. Patriarca, P. Guglielmelli, 2021, Blood Cancer Journal.

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

J. Soria, S. de Botton, V. Ribrag, 2014, Anti-cancer drugs.

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

B. Pégourié, P. Moreau, X. Leleu, 2013, Leukemia.

J. Soulier, G. Socié, J. Dalle, 2015, Blood.

Systemic Treatment Initiation in Classical and Endemic Kaposi’s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study

C. Lebbé, M. Battistella, C. Pagès, 2021, Cancers.

Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia.

K. Stegmaier, B. Schmidt, L. Benajiba, 2015, Journal of medicinal chemistry.

Baveno VII - Renewing consensus in portal hypertension.

H. Yoshiji, J. Fallowfield, V. Paradis, 2021, Journal of hepatology.

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.

I. Rozenberg, A. Risitano, G. Junge, 2021, The Lancet. Haematology.

Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure

Blandine Roux, L. Benajiba, Hélène Pasquer, 2021, Cancers.

Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia

Jen Q. Pan, K. Stegmaier, E. Scolnick, 2018, Science Translational Medicine.

Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor

S. Carr, K. Lage, K. Stegmaier, 2021, Science Translational Medicine.

Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms (MPN).

E. Clappier, W. Vainchenker, E. Raffoux, 2021, Blood.

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia

K. Stegmaier, M. Hemann, G. Alexe, 2017, Nature Medicine.

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML

K. Stegmaier, M. Hemann, J. Soulier, 2018, Leukemia.

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia

K. Owzar, A. Chilkoti, K. Wood, 2022, Nature Cancer.

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

B. Pégourié, P. Moreau, X. Leleu, 2014, Journal of Cancer.

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

T. Barbui, A. Patriarca, P. Guglielmelli, 2021, Leukemia.

Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape

S. Giraudier, J. Kiladjian, B. Cassinat, 2023, Leukemia.

Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission

W. Vainchenker, C. Chomienne, E. Raffoux, 2020 .

Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis

W. Vainchenker, E. Raffoux, C. Dosquet, 2021, Blood.

Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms

W. Vainchenker, E. Raffoux, C. Dosquet, 2021, Blood.

Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses’ infections

Anne Bergeron, J. Kiladjian, D. Michonneau, 2022, Therapies.

Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.

F. Fennessy, J. Laubach, P. Richardson, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN)

W. Vainchenker, E. Raffoux, C. Dosquet, 2020 .

Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts.

S. Orkin, K. Stegmaier, N. Gray, 2022, Cancer discovery.

Breakthrough infections in MPN-COVID vaccinated patients

M. Griesshammer, T. Barbui, A. Patriarca, 2022, Blood Cancer Journal.

Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule.

M. Sébert, L. Adès, D. Swaney, 2024, Nature cancer.

AML patient blasts exhibit polarization defect upon interaction with bone marrow stromal cells

M. Théry, B. Vianay, L. Benajiba, 2024, bioRxiv.